Roxana Dronca

13.6k total citations · 1 hit paper
109 papers, 3.8k citations indexed

About

Roxana Dronca is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Roxana Dronca has authored 109 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 43 papers in Immunology and 31 papers in Molecular Biology. Recurrent topics in Roxana Dronca's work include Cancer Immunotherapy and Biomarkers (50 papers), CAR-T cell therapy research (38 papers) and Immunotherapy and Immune Responses (33 papers). Roxana Dronca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (50 papers), CAR-T cell therapy research (38 papers) and Immunotherapy and Immune Responses (33 papers). Roxana Dronca collaborates with scholars based in United States, Australia and France. Roxana Dronca's co-authors include Svetomir N. Markovic, Haidong Dong, Aaron S. Mansfield, F. Stephen Hodi, Adil Daud, Omid Hamid, Caroline Robert, Richard Kefford, Anthony M. Joshua and Jeffrey S. Weber and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Roxana Dronca

99 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roxana Dronca United States	33	2.8k	1.4k	1.0k	771	290	109	3.8k
Elizabeth I. Buchbinder United States	23	2.9k 1.0×	1.6k 1.2×	967 1.0×	729 0.9×	312 1.1×	105	4.0k
Tara C. Gangadhar United States	32	3.0k 1.1×	1.8k 1.3×	1.0k 1.0×	565 0.7×	293 1.0×	75	4.0k
Michael A. Postow United States	15	3.0k 1.1×	1.7k 1.3×	726 0.7×	680 0.9×	249 0.9×	18	3.9k
Zeynep Eroglu United States	26	2.8k 1.0×	1.1k 0.8×	1.2k 1.2×	557 0.7×	287 1.0×	124	3.7k
Sapna P. Patel United States	29	1.8k 0.6×	1.2k 0.9×	1.5k 1.5×	473 0.6×	315 1.1×	210	3.6k
Daniela S. Thommen Netherlands	18	3.2k 1.1×	2.5k 1.8×	971 1.0×	680 0.9×	501 1.7×	38	4.5k
Anna Maria Di Giacomo Italy	31	2.8k 1.0×	1.6k 1.1×	1.1k 1.1×	1.1k 1.4×	151 0.5×	111	4.0k
Asim Amin United States	27	2.6k 0.9×	1.1k 0.8×	905 0.9×	1.1k 1.4×	431 1.5×	73	3.4k
Salvador Martín‐Algarra Spain	30	2.2k 0.8×	1.1k 0.8×	1.3k 1.3×	928 1.2×	722 2.5×	137	3.8k
Maresa Altomonte Italy	36	2.1k 0.7×	1.7k 1.2×	1.6k 1.6×	856 1.1×	346 1.2×	95	4.4k

Countries citing papers authored by Roxana Dronca

Since Specialization

Citations

This map shows the geographic impact of Roxana Dronca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roxana Dronca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roxana Dronca more than expected).

Fields of papers citing papers by Roxana Dronca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roxana Dronca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roxana Dronca. The network helps show where Roxana Dronca may publish in the future.

Co-authorship network of co-authors of Roxana Dronca

This figure shows the co-authorship network connecting the top 25 collaborators of Roxana Dronca. A scholar is included among the top collaborators of Roxana Dronca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roxana Dronca. Roxana Dronca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luo, Yan, Martha E. Gadd, Yaqing Qie, et al.. (2024). Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1. SHILAP Revista de lepidopterología. 32(4). 200891–200891. 4 indexed citations

Asiedu, Gladys B., Mary Ellen Young, Folakemi T. Odedina, et al.. (2024). Abstract 1310: Social determinants of migrant health factors impacting prostate cancer care and survivorship among sub-Saharan African immigrant men diagnosed with prostate cancer. Cancer Research. 84(6_Supplement). 1310–1310. 1 indexed citations

Kharfan‐Dabaja, Mohamed A., Vivek Roy, Hemant S. Murthy, et al.. (2023). Post-Autologous Hematopoietic Cell Transplant Care in the “Home Sweet Home” Setting: A Treatment Paradigm Shift. Hematology/Oncology and Stem Cell Therapy. 16(4). 407–411. 2 indexed citations

ReFaey, Karim, Shashwat Tripathi, Sanjeet S. Grewal, et al.. (2021). Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. SHILAP Revista de lepidopterología. 5(3). 645–653. 38 indexed citations

Hieken, Tina J., Amy E. Glasgow, Elizabeth Ann L. Enninga, et al.. (2020). Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. Journal of Women s Health. 29(9). 1160–1167. 23 indexed citations

Karp, Daniel D., Roxana Dronca, D. Ross Camidge, et al.. (2020). 1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours. Annals of Oncology. 31. S708–S708. 5 indexed citations

DeLeon, Thomas, Daniel Almquist, Benjamin R. Kipp, et al.. (2020). Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS ONE. 15(3). e0230306–e0230306. 23 indexed citations

Hamid, Omid, Anthony M. Joshua, Antoni Ribas, et al.. (2020). 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma. Annals of Oncology. 31. S762–S763. 2 indexed citations

Marin‐Acevedo, Julian A., Răzvan M. Chirilă, & Roxana Dronca. (2019). Immune Checkpoint Inhibitor Toxicities. Mayo Clinic Proceedings. 94(7). 1321–1329. 105 indexed citations

10.

Barham, Whitney, Joanina K. Gicobi, Yiyi Yan, Roxana Dronca, & Haidong Dong. (2019). Paradox-driven adventures in the development of cancer immunology and immunotherapy. Genes & Diseases. 6(3). 224–231. 4 indexed citations

11.

Mansfield, Aaron S., Hongzheng Ren, Shari L. Sutor, et al.. (2018). Contraction of T cell richness in lung cancer brain metastases. Scientific Reports. 8(1). 2171–2171. 65 indexed citations

12.

Yan, Yiyi, Anagha Kumar, Heidi D. Finnes, et al.. (2018). Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology. 9. 1739–1739. 182 indexed citations

13.

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

14.

Enninga, Elizabeth Ann L., Justin C. Moser, Amy L. Weaver, et al.. (2017). Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Medicine. 6(10). 2203–2212. 101 indexed citations

15.

Youland, Ryan S., Annie T. Packard, Andrea Arnett, et al.. (2017). 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Advances in Radiation Oncology. 2(2). 204–210. 10 indexed citations

16.

Dronca, Roxana & Haidong Dong. (2015). A Gender Factor in Shaping T-Cell Immunity to Melanoma. Frontiers in Oncology. 5. 8–8. 12 indexed citations

17.

Dronca, Roxana, et al.. (2014). Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. Mayo Clinic Proceedings. 89(4). 504–519. 74 indexed citations

18.

Dronca, Roxana, Jacob B. Allred, Domingo G. Pérez, et al.. (2013). Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma. American Journal of Clinical Oncology. 37(4). 369–376. 35 indexed citations

19.

Parikh, Sameer A., Christopher A. French, Brian A. Costello, et al.. (2013). NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm. Journal of Thoracic Oncology. 8(10). 1335–1338. 34 indexed citations

20.

Dronca, Roxana, Dragan Jevremović, Curtis A. Hanson, et al.. (2010). CD5‐positive chronic B‐cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity. Cytometry Part B Clinical Cytometry. 78B(S1). S35–41. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact